Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease (Q37620347)

21 August 2017

1 reference

title

Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease (English)

1 reference

21 August 2017

1

Monique P Curran

1 reference

21 August 2017

Dean M Robinson

2

1 reference

21 August 2017

1 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

69

1 reference

21 August 2017

16

1 reference

21 August 2017

2329-2349

1 reference

https://scigraph.springernature.com/pub.10.2165/11202610-000000000-00000

21 August 2017

0 references

cites work

Guidelines for the management of chronic kidney disease

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11202610-000000000-00000

Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11202610-000000000-00000

Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin

21 January 2018

1 reference

12 December 2020

A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate

1 reference

12 December 2020

Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.

1 reference

12 December 2020

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial

1 reference

12 December 2020

Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.

1 reference

12 December 2020

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate

1 reference

12 December 2020

Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis

1 reference

12 December 2020

Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?

1 reference

12 December 2020

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis

1 reference

12 December 2020

The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease

1 reference

12 December 2020

Hyperphosphatemia of chronic kidney disease

1 reference

12 December 2020

Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis

1 reference

12 December 2020

A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients

1 reference

12 December 2020

Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate.

1 reference

12 December 2020

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease

1 reference

12 December 2020

Nocturnal home hemodialysis and short daily hemodialysis compared with kidney transplantation: emerging data in a new era.

1 reference

12 December 2020

A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease

1 reference

12 December 2020

Biochemical and hematological changes in low-level aluminum intoxication

1 reference

12 December 2020

Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study

1 reference

12 December 2020

Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia.

1 reference

12 December 2020

Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.

1 reference

12 December 2020

Fifteen years of clinical experience with daily haemodialysis

1 reference

12 December 2020

Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia

1 reference

12 December 2020

Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review

1 reference

12 December 2020

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

1 reference

12 December 2020

Emerging strategies for lowering serum phosphorous in patients with end-stage renal disease

1 reference

12 December 2020

Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology

1 reference

12 December 2020

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy

1 reference

12 December 2020

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

1 reference

12 December 2020

The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone

1 reference

12 December 2020

Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

1 reference

12 December 2020

Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride

1 reference

12 December 2020

Oral phosphate binders for the management of serum phosphate levels in dialysis patients

1 reference

12 December 2020

Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis

1 reference

12 December 2020

Hyperphosphataemia in renal failure: causes, consequences and current management

1 reference

12 December 2020

Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.

1 reference

12 December 2020

The role of magnesium binders in chronic kidney disease

1 reference

12 December 2020

Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

1 reference

12 December 2020

1 reference

12 December 2020

Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate.

1 reference

12 December 2020

A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis

1 reference

12 December 2020

Serum phosphate levels and mortality risk among people with chronic kidney disease

1 reference

12 December 2020

Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden

1 reference

12 December 2020

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

1 reference

12 December 2020

Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.

1 reference

12 December 2020

Clinical pharmacokinetics of the phosphate binder lanthanum carbonate

1 reference

12 December 2020

Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact?

1 reference

12 December 2020

Oral phosphate binders

1 reference

12 December 2020

Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate

1 reference

12 December 2020

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

1 reference

12 December 2020

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment

1 reference

12 December 2020

Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study

1 reference

12 December 2020

Phosphate is a uremic toxin

1 reference

12 December 2020

High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients

1 reference

12 December 2020

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

1 reference

12 December 2020

Vascular calcification in chronic renal failure

1 reference

12 December 2020

Medication use among dialysis patients in the DMMS. United States Renal Data System. Dialysis Morbidity and Mortality Study

1 reference

12 December 2020

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

1 reference

12 December 2020

Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study

1 reference

12 December 2020

The clinical management of hyperphosphatemia

1 reference

12 December 2020

Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study

1 reference

12 December 2020

10.2165/11202610-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

19852531

Dimensions Publication ID

21 August 2017

0 references

1 reference

PubMed ID

19852531